Best Healthcare Technology Stocks To Watch For 2014

BALTIMORE (Stockpickr) -- Don't be fooled by last week's bounce -- some stocks are still looking toxic right now.

Despite a big bounce last Wednesday, the S&P 500 is actually down 0.14% since the Fed announced that the taper caper was off. If the end to QE was really priced into the market, as so many said, then stocks sure aren't showing it. While the broad market still looks bullish overall, owning weak individual names is still a big liability in this market.

That's why we're taking a closer look at five "toxic" stocks you should sell today. Now. To be fair, the companies I'm talking about today aren't exactly "junk."

By that, I mean they're not next up in line at bankruptcy court. But that's frankly irrelevant; from a technical analysis standpoint, they're some of the worst positioned names out there right now. For that reason, fundamental investors need to decide how long they're willing to take the pain if they want to hold onto these firms this summer. And for investors looking to buy one of these positions, it makes sense to wait for more favorable technical conditions (and a lower share price) before piling in.

10 Best Healthcare Equipment Stocks To Buy For 2015: Chino Commercial Bancorp (CCBC)

Chino Commercial Bancorp, incorporated on March 2, 2006, is a bank holding company of Chino Commercial Bank, N.A. (the Bank). The Bank provides a wide variety of lending products for both businesses and consumers. The Bank offers an array of personal, consumer and commercial services generally offered by a locally-managed, independently-operated bank. The Bank provides a range of deposit instruments and general banking services, including checking, savings accounts (including money market demand accounts), certificates of deposit for both business and personal accounts; Internet banking services, such as cash management and Bill Pay; telebanking (banking by phone); and courier services. The Bank operates three full-service banking offices.

Lending Activities

Commercial loan products include lines of credit, letters of credit, term loans, equipment loans, commercial real estate loans, construction loans, accounts receivable financing, working capital financing. Financing products for individuals include auto, home equity, overdraft protection lines and, through a third party provider, MasterCard debit cards. Real estate loan products include construction loans, land loans, mini-perm commercial real estate loans, and home mortgages. As of December 31, 2011, the Company had total assets of $109.7 million and net loans of $55.2 million. Its lending activity is concentrated primarily in real estate loans, which constituted 81.3% of the Company�� loan portfolio as of December 31, 2011, and commercial loans, which constituted 17.6%, of the Company�� loan portfolio as of December 31, 2011.

Investment activities

The Company�� investment security portfolio consists of United States government agency securities, mortgaged-backed securities, municipal bonds and corporate bonds. Investment securities held to maturity are carried at cost, which equates to the unpaid principal balances adjusted for amortization of premium and accretion of discounts.

Sources of funds

Deposits are the Company�� primary source of funds. As of December 31, 2011, the Company�� total deposits were $98.1 million. As of December 31, 2011, its deposits included demand deposits, negotiable order of withdrawal (NOW), savings deposits, money market and time deposits.

Advisors' Opinion:

• [By Lisa Levin]

  Regional - Pacific Banks: This industry rose 1.54% by 10:40 am ET. The top performer in this industry was Chino Commercial Bancorp (OTC: CCBC), which gained 10.2%. Chino Commercial Bancorp's trailing-twelve-month operating margin is 27.57%.

Best Healthcare Technology Stocks To Watch For 2014: iShares MSCI Japan ETF (EWJ)

iShares MSCI Japan Index Fund (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of publicly traded securities in the aggregate in the Japanese market, as measured by the MSCI Japan Index (the Index). The Index seeks to measure the performance of the Japanese equity market. The Index is a capitalization-weighted index that aims to capture 85% of the (publicly available) total market capitalization. Component companies are adjusted for available float and must meet objective criteria for inclusion in the Index. The Index is reviewed quarterly.

The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. iShares MSCI Japan Index Fund's investment advisor is Barclays Global Fund Advisors.

Advisors' Opinion:

• [By Stephen Leeb, Founder and Research Chairman, Leeb Group]

  Despite the 30% plus gains they've enjoyed this year, the stocks that comprise the iShares MSCI Japan ETF (EWJ) still trade at 14 times depressed earnings.

Best Healthcare Technology Stocks To Watch For 2014: Invesco Mortgage Capital Inc (IVR)

Invesco Mortgage Capital Inc., incorporated in June 2008, is a real estate investment trust (REIT). The Company is primarily focused on investing in, financing and managing residential and commercial mortgage-backed securities and mortgage loans, which it collectively refers to as its target assets. The Company�� target assets consist of residential mortgage-backed securities (RMBS) for which the United States Government agency, such as the Government National Mortgage Association (Ginnie Mae) or a federally chartered corporation, such as the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac) guarantees payments of principal and interest on the securities. It refers to these securities as Agency RMBS. Its Agency RMBS investments include mortgage pass-through securities and may include collateralized mortgage obligations (CMOs). It also invests in RMBS that are not issued or guaranteed by the United States Government agency (non-Agency RMBS), commercial mortgage-backed securities (CMBS) and residential and commercial mortgage loans.

The Company finances its Agency RMBS, non-Agency RMBS and CMBS investments through short-term borrowings structured as repurchase agreements. The Company�� manager is Invesco Advisors Inc. The Company also finances its investments in certain non-Agency RMBS, CMBS and residential and commercial mortgage loans by contributing capital to the Invesco Mortgage Recovery Feeder Fund (Invesco IMRF Fund) that invests in public-private investment funds (PPIF) managed by the Company�� manager. The Company's manager is a wholly owned subsidiary of Invesco Ltd.

Advisors' Opinion:

• [By Amanda Alix]

  All mREITs are taking it on the chin
  The agency crew, led by heavy hitters Annaly Capital (NYSE: NLY  ) , American Capital Agency (NASDAQ: AGNC  ) , and Armour Residential (NYSE: ARR  ) , have all been close to hitting 52-week lows, but the blood-letting hasn't stopped there. Even hybrid mortgage REITs, which also buy some non-agency paper, have plunged, as well. Two Harbors (NYSE: TWO  ) , which enjoyed such a nice lift post-earnings about a month ago, recently sunk to new lows, and Invesco Mortgage Capital (NYSE: IVR  ) has also slipped, even after its CIO's recent show of faith, making a sizable insider purchase�of stock less than two weeks ago.

• [By Sean Williams]

  In contrast, non-agency mREITs often have to be more careful with their leverage since loan defaults actively impact their bottom-line profit, and rapidly rising interest rates, such as what we saw over the past few weeks, can trigger MBS and other security sales at a loss. In return for more risk, non-agency securities pay out higher yields. Take, for example, Invesco Mortgage Capital (NYSE: IVR  ) , a buyer of agency and non-agency RMBSes, which delivered what might seem like an uninspiring 1.64% net interest margin in the first quarter with a leverage ratio of 6.4. Now compare that to agency-only mREIT Annaly Capital, whose net interest margin fell 80 basis points from the year-ago period in the first quarter to just 0.91%, but with a higher leverage ratio of 6.6.

• [By Monica Wolfe]

  Invesco Mortgage Capital (IVR)

  President and CEO of Invesco Richard King reported a rather notable insider buy on Aug. 5. The CEO purchased 6,500 shares of company stock at an average price of $15.41 per share. This purchase cost King a total of $100,165. Since this buy, the share price has increased a minor 0.13%. King now holds on to at least 56,545 shares of Invesco Mortgage stock.

Best Healthcare Technology Stocks To Watch For 2014: Central Fund of Canada Limited (CEF)

Central Fund of Canada is an closed-ended commodity mutual fund launched and managed by Central Group Alberta, Ltd. It invests in the commodity markets. The fund primarily invests in commodities like silver and gold. Central Fund of Canada was formed on November 15, 1961 and is domiciled in Canada.

Advisors' Opinion:

• [By Eric Parnell]

  It also remains worthwhile to hedge stock allocations to protect against any major downside event along the way. This includes positions with low correlations such as the PIMCO Total Return ETF (BOND) or the PIMCO Global Advantage Inflation Linked Bond ETF (ILB). This also includes allocations that are likely to rally sharply in the event of a stock pullback but can also continue to rise along with the market such as long-term Treasuries (TLT) or Build America Bonds (BAB). And despite the recent thrashing they have endured, the precious metals complex including gold (GLD), silver (SLV), platinum (PPLT) and palladium (PALL) continue to provide attractive long-term portfolio diversification benefits. I remain long all of these metals via the Central GoldTrust (GTU), the Central Fund of America (CEF), the Sprott Physical Silver Trust (PSLV) and the Sprott Physical Platinum and Palladium Trust (SPPP).

Best Healthcare Technology Stocks To Watch For 2014: Blackrock Enhanced Equity Dividend Trust (BDJ)

BlackRock Enhanced Dividend Achievers Trust (the Trust) is a diversified closed-end management investment company. The Trust�� primary investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve these objectives by investing in common stocks that pay above average dividends and have the potential for capital appreciation and by utilizing an option writing strategy to enhance distributions paid to the Trust�� shareholders.

Under normal market conditions, the Trust will invest at least 80% of its total assets in common stocks that are included in the universe of common stocks of issuers, which Mergent has determined are Dividend Achievers and options with exposure to such stocks. From time to time, the Trust may invest up to 20% of its total assets in investments without exposure to the Dividend Achievers universe. As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call and put options on individual common stocks, indices of securities, sectors of securities and baskets of securities.

Advisors' Opinion:

• [By Robert Hsu]
  Name Type of Security� Recommendation� Kinder Morgan Energy Partners L.P. (NYSE: KMP) � MLP August 15, 2013� TeeKay LNG Partners L.P.� (NYSE: TGP) � MLP September 16, 2013� PowerShares S&P 500 BuyWrite Portfol ETF� (NYSE Arca: PBP)� Buy-Write ETF September 30, 2013� Madison Covered Call Equity Strtgy Fd (NYSE: MCN)� Buy-Write ETF September 30, 2013� Nuveen Equity Premium Opportunity Fund (NYSE: JSN)� Buy-Write ETF September 30, 2013� BlackRockEnhanced Dividend Achievers Tr (NYSE: BDJ)� Buy-Write ETF September 30, 2013� Vornado Realty Trust � (NYSE: VNO)� Real Estate
  Investment
  Trust September 26, 2013�
  
  

  Robert Hsu is the editor of Permanent Wealth Investor and a former hedge fund portfolio manager at Wall Street powerhouse Goldman Sachs. He retired from Goldman at age 31. He since has come out of retirement to establish and preside over his money management firm, Absolute Return Capital Advisors. His retirement experience has given him his current mission: helping investors like you achieve their goal of comfortable retirement through profitable income strategies.

Best Healthcare Technology Stocks To Watch For 2014: QC Holdings Inc.(QCCO)

QC Holdings, Inc. provides various retail consumer financial products and services in the United States. The company offers payday loans that provide cash to the customers in exchange for a promissory note with a maturity of two to three weeks. It also provides financial products and services, such as installment loans, credit services, check cashing services, title loans, money transfers, and money orders. In addition, QC Holdings operates as a credit services organization that arranges a third-party lender to make a loan to the consumer and for providing related services to the consumer, including a guarantee of the consumer?s obligation to the third-party lender. Further, the company sells used vehicles and earns finance charges from the related vehicle financing contracts; and provides reconditioning services on its inventory of vehicles, and repair services for its customers. As of As of December 31, 2010, the company operated 523 short-term lending branches in 24 sta tes; and 5 buy here, pay here lots located in Missouri and Kansas. QC Holdings, Inc. was founded in 1984 and is headquartered in Overland Park, Kansas.

Advisors' Opinion:

• [By Lisa Levin]

  QC Holdings (NASDAQ: QCCO) shares tumbled 3.68% to reach a new 52-week low of $1.83. QC Holdings shares have dropped 42.60% over the past 52 weeks, while the S&P 500 index has gained 31.67% in the same period.

• [By Monica Gerson]

  QC Holdings (NASDAQ: QCCO) shares tumbled 2.58% to reach a new 52-week low of $2.27. QC Holdings' trailing-twelve-month profit margin is 0.60%.

  NewLead Holdings (NASDAQ: NEWL) shares dipped 6.56% to touch a new 52-week low of $0.08 after the company completed the acquisition of titles in the Viking Mine located in Kentucky, USA.

Best Healthcare Technology Stocks To Watch For 2014: Durata Therapeutics Inc (DRTX)

Durata Therapeutics, Inc., incorporated on November 4, 2009, is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia.

As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin. Dalbavancin achieved its primary efficacy endpoint of non-inferiority in each of these three completed Phase III clinical trials when compared to linezolid, cefazolin or vancomycin, three of the standard-of-care agents for uncomplicated skin and skin structure infections (uSSSI), and complicated skin and skin structure infections (cSSSI). Its two ongoing Phase III clinical trials are designed to compare dalbavancin to vancomycin, with an option to switch to oral linezolid, under the new FDA draft guidance.

The Company competes with Pfizer, Cubist Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., Sanofi-Aventis Ltd., The Medicines Company, Trius Therapeutics, Inc., Cempra, Inc., Rib-X Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc., Nabriva Therapeutics AG, Tetraphase Pharmaceuticals, Inc. and Furiex Pharmaceuticals, Inc.

Advisors' Opinion:

• [By Bob's Stocks]

  Durata Therapeutics (DRTX) is developing Dalbavancin, a once a week, intravenous antibiotic product candidate, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. The company is expected to file a NDA (New Drug Application) at any moment and MAA (Marketing Authorization Application) at the end of 2013.

• [By Lisa Levin]

  Durata Therapeutics (NASDAQ: DRTX) shares climbed 5.30% to $14.18. The volume of Durata Therapeutics shares traded was 861% higher than normal. The FDA Advisory Committee unanimously recommended the approval of Durata's Dalvance.